BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanlon P, Corcoran N, Rughani G, Shah ASV, Mair FS, Guthrie B, Renton JP, McAllister DA. Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people. Lancet Healthy Longev 2021;2:e398-406. [PMID: 34240062 DOI: 10.1016/S2666-7568(21)00092-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanlon P, Butterly E, Shah ASV, Hannigan LJ, Wild SH, Guthrie B, Mair FS, Dias S, Welton NJ, McAllister DA. Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data. BMC Med 2022;20:410. [PMID: 36303169 DOI: 10.1186/s12916-022-02594-9] [Reference Citation Analysis]
2 Sheppard JP, Benetos A, McManus RJ. Antihypertensive Deprescribing in Older Adults: a Practical Guide. Curr Hypertens Rep 2022. [PMID: 35881225 DOI: 10.1007/s11906-022-01215-3] [Reference Citation Analysis]
3 Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, Boyd CM, Pati S, Mtenga S, Smith SM. Multimorbidity. Nat Rev Dis Primers 2022;8:48. [PMID: 35835758 DOI: 10.1038/s41572-022-00376-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Sheppard JP. Applying clinical trial evidence on antihypertensive therapy to older adults in the community. The Lancet Healthy Longevity 2021. [DOI: 10.1016/s2666-7568(21)00139-2] [Reference Citation Analysis]